|Trade names||Marezine, Valoid, Nausicalm, others|
|by mouth, IM, IV|
|Defined daily dose||0.1 mg(by mouth)|
0.1 mg (parenteral)
0.3 mg( rectal)
|AHFS/Drugs.com||Consumer Drug Information|
|Metabolism||N-demethylated to inactive norcyclizine|
|Elimination half-life||20 hours|
|Chemical and physical data|
|Molar mass||266.388 g·mol−1|
|3D model (JSmol)|
Cyclizine, sold under a number of brand names, is a medication used to treat and prevent nausea, vomiting and dizziness due to motion sickness or vertigo. It may also be used for nausea after general anaesthesia or that which developed from opioid use. It is taken by mouth, in the rectum, or injected into a vein.
Common side effects include sleepiness, dry mouth, constipation, and trouble with vision. More serious side effects include low blood pressure and urinary retention. It is not generally recommended in young children or those with glaucoma. Cyclizine appears to be safe during pregnancy but has not been well studied. It is in the anticholinergic and antihistamine family of medications.
Cyclizine was discovered in 1947. It is on the World Health Organization's List of Essential Medicines. In the United States it is available over the counter. In the United Kingdom 100 tablets costs about £11.26. It is occasionally used for the "high" it can create.
Primary uses include nausea, vomiting and dizziness associated with motion sickness, vertigo and post-operatively following administration of general anesthesia and opioids. It is sometimes given in hyperemesis gravidarum, although the manufacturer advises that it be avoided in pregnancy. Off-license use often occurs with specialists in hospitals to treat inpatients who have become severely dehydrated in pregnancy. An off-label use is as an opioid/opiate potentiator.
Uncommon (1% to 10%) — Headache, psychomotor impairment, dermatitis, and antimuscarinic effects such as diplopia (double vision), tachycardia, constipation, urinary retention and gastro-intestinal disturbances.
Rare (less than 1%) — Hypersensitivity reactions (bronchospasm, angioedema, anaphylaxis, rashes and photosensitivity reactions), extrapyramidal effects, dizziness, confusion, depression, sleep disturbances, tremor, liver dysfunction, and hallucinations.
Cyclizine is a piperazine derivative with histamine H1-receptor antagonist (antihistamine) activity. The precise mechanism of action in inhibiting the symptoms of motion sickness is not well understood. It may have effects directly on the vestibular system and on the chemoreceptor trigger zone. Cyclizine exerts a central anticholinergic (antimuscarinic) action.
Cyclizine may be prepared by the Eschweiler–Clarke methylation of diphenylmethylpiperazine or by reaction of benzhydryl bromide with 1-methylpiperazine in acetonitrile to form the hydrobromide salt of the drug.
Cyclizine was developed in the American division of pharmacy company Burroughs Wellcome (today GlaxoSmithKline) during a research study involving many drugs of the antihistamine group. Cyclizine was quickly clinically found as a potent and long-acting antiemetic. The company named the substance – or more precisely cyclizine's hydrochloride form which it usually appears in – "marezine hydrochloride" and started to sell it in the United States under trade name Marezine. Selling was begun in France under trade name Marzine in 1965.
The substance received more credit when NASA chose it as a space antiemetic for the first occupied moon flight. Cyclizine was introduced to many countries as a common antiemetic. It is an over-the-counter drug in many countries because it has been well tolerated, although it has not been studied much.
Society and culture
Some people using methadone recreationally combine cyclizine with their methadone dose, a combination that is known to produce strong psychoactive effects. It has also been used recreationally for its anticholinergic effects to induce hallucinations.
As cyclizine hydrochloride tablets and cyclizine lactate solution for intramuscular or intravenous injection (brand names: Valoid in UK and South Africa and Marezine, Marzine and Emoquil in US). Cyclizine was marketed as Bonine for Kids in the US, but was discontinued in 2012, and replaced with meclizine.
|Structural comparison of cyclizine |
and related H1 antagonists
- "WHOCC - ATC/DDD Index". www.whocc.no. Retrieved 20 September 2020.
- "DrugBank: Cyclizine. Pharmacology: metabolism". DrugBank Database. Archived from the original on 30 January 2016. Retrieved 5 January 2016.
- "Cyclizine 50mg Tablets - Summary of Product Characteristics (SPC) - (eMC)". www.medicines.org.uk. 27 March 2015. Archived from the original on 20 December 2016. Retrieved 13 December 2016.
- Feldman, Mark; Friedman, Lawrence S.; Brandt, Lawrence J. (2015). Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. Elsevier Health Sciences. p. 218. ISBN 9781455749898. Archived from the original on 20 December 2016. Unknown parameter
- World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- "Cyclizine Side Effects in Detail - Drugs.com". www.drugs.com. Archived from the original on 21 December 2016. Retrieved 13 December 2016.
- "Cyclizine: Indications, Side Effects, Warnings - Drugs.com". www.drugs.com. Archived from the original on 21 December 2016. Retrieved 13 December 2016.
- "Cyclizine Use During Pregnancy | Drugs.com". www.drugs.com. Archived from the original on 21 December 2016. Retrieved 13 December 2016.
- Williams, Peter (2010). The story of the Wellcome Trust : unlocking Sir Henry's legacy to medical research. Hindringham: JJG. p. 14. ISBN 9781899163922. Archived from the original on 20 December 2016. Unknown parameter
- British national formulary : BNF 69 (69 ed.). British Medical Association. 2015. p. 272. ISBN 9780857111562.
- "Valoid Tablets by Amdipharm". Electronic Medicines Compendium. Datapharm. Archived from the original on 4 March 2016. Retrieved 1 October 2011.
- "Diconal Tablets by Amdipharm". Electronic Medicines Compendium. Datapharm. Archived from the original on 1 April 2008. Retrieved 5 August 2008.
- "Conversion Factors for Controlled Substances". DEA Diversion Control Division. Retrieved 26 March 2020.
Sneader, Walter (2005). Drug discovery: a history. John Wiley & Sons. p. 404. ISBN 0-471-89979-8. Archived from the original on 10 September 2017. Unknown parameter
Sittig, Marshall (1988). Pharmaceutical manufacturing encyclopedia. William Andrew. p. 406. ISBN 0-8155-1144-2. Archived from the original on 10 September 2017. Unknown parameter
- "Archived copy". Archived from the original on 2 April 2015. Retrieved 9 March 2015.CS1 maint: archived copy as title (link)
- Ruben SM, McLean PC, Melville J (August 1989). "Cyclizine abuse among a group of opiate dependents receiving methadone". British Journal of Addiction. 84 (8): 929–34. doi:10.1111/j.1360-0443.1989.tb00766.x. PMID 2775912.
- Bassett KE, Schunk JE, Crouch BI (September 1996). "Cyclizine abuse by teenagers in Utah". The American Journal of Emergency Medicine. 14 (5): 472–4. doi:10.1016/S0735-6757(96)90156-4. PMID 8765114.
- Conor Ryan for The Independent. June 20, 2013 IGB left with €250k bill after dog doping case Archived 2016-03-04 at the Wayback Machine
- "Bonine for Kids". Insight Pharmaceuticals. Archived from the original on 17 September 2010.
- Lemke, Thomas L.; Williams, David A.; Roche, Victoria F.; Zito, S. William, eds. (2013). Foye's Principles of Medicinal Chemistry (7th ed.). Philadelphia: Wolters Kluwer Health / Lippincott Williams & Wilkins. p. 1056. ISBN 978-1-60913-345-0. Unknown parameter